See the DrugPatentWatch profile for Vyjuvek
What is Vyjuvek’s approval status in 2026?
Vyjuvek (beremagene geperpavec-svdb) is an FDA-approved treatment for epidermolysis bullosa (EB) in people with dystrophic EB (including some severe forms), where it is used to help heal wounds. Its continued marketing/availability depends on ongoing compliance, supply, and labeling updates rather than annual “re-approval.” [1]
Is Vyjuvek approved in the U.S., or is it still pending?
Vyjuvek is approved by the U.S. Food and Drug Administration (FDA), so it is not in a “pending” approval status in the U.S. for EB based on FDA action. If you are asking about 2026 specifically, the key point is that FDA approval is already in place; 2026-related changes would typically come from label updates, expanded indications, post-approval study results, or safety communications rather than a new approval cycle. [1]
Has Vyjuvek’s indication or labeling changed since the original approval?
Changes to Vyjuvek’s approved use would show up as updates to the FDA label (for example, changes to the description of eligible EB type/severity, dosing/application instructions, or warnings). The most reliable way to verify the exact scope “in 2026” is to check the current FDA labeling for Vyjuvek, since that reflects the latest approved status. [1]
Where can I verify the most current “2026” status?
The FDA’s product page for Vyjuvek and the current FDA label are the authoritative sources for confirming what is approved now (including whether there have been label revisions, indication changes, or updated prescribing information). [1]
What if you mean approval in countries other than the U.S.?
“Approval status 2026” can differ by country. The FDA confirmation covers the U.S. only. To check approvals outside the U.S., you would need the relevant regulator’s database (for example, EMA and member-state pathways in Europe) or the product’s local authorization listing. [1]
Sources
- FDA – Vyjuvek (beremagene geperpavec-svdb) prescribing information and product page